Dietmar Berger | BiotechTV

top of page

ASCO 2026: Gilead CMO Dietmar Berger discusses the company's cell therapy and antibody-drug conjugate approaches in oncology, and shares the rationale on four recent acquisitions

On the ADC front, he discusses Trodelvy's role in triple-negative breast cancer and the rationale for acquiring Tubulis for its next generation ADC pipeline. Plus, BCMA CAR-T (the acquisition of Arcellx), treating glioblastoma with CAR-T, and the future of in vivo cell therapy.

Company News

2 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

ASCO 2026: Gilead CMO Dietmar Berger discusses the company's cell therapy and antibody-drug conjugate approaches in oncology, and shares the rationale on four recent acquisitions

Follow BiotechTV

Sponsors

Sponsor Spotlight